Logo image of ZYBT

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis

NASDAQ:ZYBT - KYG989MS1016 - Common Stock

9.36 USD
+0.49 (+5.52%)
Last: 8/29/2025, 8:00:54 PM
9.3 USD
-0.06 (-0.64%)
After Hours: 8/29/2025, 8:00:54 PM
Fundamental Rating

5

ZYBT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. ZYBT has an average financial health and profitability rating. While showing a medium growth rate, ZYBT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year ZYBT was profitable.
In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

The Return On Assets of ZYBT (7.96%) is better than 91.19% of its industry peers.
ZYBT has a Return On Equity of 13.83%. This is amongst the best in the industry. ZYBT outperforms 88.60% of its industry peers.
Looking at the Return On Invested Capital, with a value of 12.67%, ZYBT belongs to the top of the industry, outperforming 90.67% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ZYBT is below the industry average of 15.38%.
The last Return On Invested Capital (12.67%) for ZYBT is above the 3 year average (10.57%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.96%
ROE 13.83%
ROIC 12.67%
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 5 10 15

1.3 Margins

ZYBT's Profit Margin of 12.95% is amongst the best of the industry. ZYBT outperforms 88.08% of its industry peers.
In the last couple of years the Profit Margin of ZYBT has declined.
ZYBT has a Operating Margin of 16.66%. This is amongst the best in the industry. ZYBT outperforms 86.01% of its industry peers.
In the last couple of years the Operating Margin of ZYBT has declined.
ZYBT has a better Gross Margin (54.00%) than 64.25% of its industry peers.
ZYBT's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.66%
PM (TTM) 12.95%
GM 54%
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZYBT is still creating some value.
Compared to 1 year ago, ZYBT has about the same amount of shares outstanding.
Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 9.88 indicates that ZYBT is not in any danger for bankruptcy at the moment.
ZYBT has a better Altman-Z score (9.88) than 86.53% of its industry peers.
ZYBT has a debt to FCF ratio of 6.51. This is a slightly negative value and a sign of low solvency as ZYBT would need 6.51 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.51, ZYBT belongs to the top of the industry, outperforming 80.31% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that ZYBT is not too dependend on debt financing.
ZYBT has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 6.51
Altman-Z 9.88
ROIC/WACC1.45
WACC8.72%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

ZYBT has a Current Ratio of 1.31. This is a normal value and indicates that ZYBT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.31, ZYBT is doing worse than 72.54% of the companies in the same industry.
ZYBT has a Quick Ratio of 1.31. This is a bad value and indicates that ZYBT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ZYBT (0.88) is worse than 77.20% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 0.88
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ZYBT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.94%, which is quite impressive.
ZYBT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 528.02% yearly.
Looking at the last year, ZYBT shows a very strong growth in Revenue. The Revenue has grown by 43.18%.
ZYBT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 854.79% yearly.
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 78.00, ZYBT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ZYBT is valued a bit cheaper than 76.68% of the companies in the same industry.
ZYBT's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.08.
Industry RankSector Rank
PE 78
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

78.24% of the companies in the same industry are more expensive than ZYBT, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZYBT indicates a somewhat cheap valuation: ZYBT is cheaper than 75.65% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 238.32
EV/EBITDA 41.02
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

ZYBT has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (8/29/2025, 8:00:54 PM)

After market: 9.3 -0.06 (-0.64%)

9.36

+0.49 (+5.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.1%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap443.57M
AnalystsN/A
Price TargetN/A
Short Float %5.42%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 78
Fwd PE N/A
P/S 10.43
P/FCF 238.32
P/OCF 77.07
P/B 11.14
P/tB 12.11
EV/EBITDA 41.02
EPS(TTM)0.12
EY1.28%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY0.42%
OCF(TTM)0.12
OCFY1.3%
SpS0.9
BVpS0.84
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.96%
ROE 13.83%
ROCE 14.13%
ROIC 12.67%
ROICexc 13.42%
ROICexgc 14.4%
OM 16.66%
PM (TTM) 12.95%
GM 54%
FCFM 4.38%
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexcg growth 3Y-33.64%
ROICexcg growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 6.51
Debt/EBITDA 0.06
Cap/Depr 114.94%
Cap/Sales 9.16%
Interest Coverage 12.67
Cash Conversion 54.97%
Profit Quality 33.8%
Current Ratio 1.31
Quick Ratio 0.88
Altman-Z 9.88
F-Score7
WACC8.72%
ROIC/WACC1.45
Cap/Depr(3y)102.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36165%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y85057.7%
OCF growth 3Y988.8%
OCF growth 5YN/A